NEW HAVEN, Conn., January 22, 2008— Carigent Therapeutics, Inc., announced today that the National Science Foundation has awarded Carigent a six-month, $97,000 Phase I Small Business Innovation Research (SBIR) grant to engineer long-circulating nanoparticles that target delivery and enable controlled release of paclitaxel to ovarian cancer tumors.
